Article Per Year (5 Year)
p-Index From 2019 - 2024
0.444
P-Index
This Author published in this journals
All Journal JURNAL ILMU KEFARMASIAN INDONESIA Jurnal Multidisiplin Madani (MUDIMA) Journal of Global Pharma Technology
YAHDIANA HARAHAP
UNIVERSITAS INDONESIA
Civil Engineering, Building, Construction & Architecture Decision Sciences, Operations Research & Management Economics, Econometrics & Finance Industrial & Manufacturing Engineering Medicine & Pharmacology Social Sciences

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Penggunaan Obat Herbal pada Pasien Kanker Serviks MAKSUM RADJI; HENDRI ALDRAT; YAHDIANA HARAHAP; COSPHIADI IRAWAN
JURNAL ILMU KEFARMASIAN INDONESIA Vol 8 No 1 (2010): JIFI
Publisher : Fakultas Farmasi Universitas Pancasila

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1717.125 KB)

Abstract

Herbal medicines have widely been used to treat many type of diseases despite the advance of standard or conventional therapy. In fact, many people in Indonesia use medicinal plant as their customary part of life. Therefore, it is necessary to further explore the use of herbal medicines through modern perception. ln this study we would like to know the frequency and species of herbal medicines used among cervical cancer patients in National Cancer Hospital Dharmais, Jakarta, Indonesia and also to assess the relationship between age, education, jobs, stage of cancer, and payment status of the patients. The results were 61,8% patients used herbal medicines. The herbal medicines used most were mahkota dewa (Phaleria macrocarpa Scheetf Boerl.) 35.3%, temu putih (Curcuma zedoaria Rosc.) 32.4%, and buah merah (Pandanus conoideus Lam) 17,6%. There was a significant relationship (p=0,039) between the use of herbal medicines and stage of cancer but no relationship between age, education, occupation, income and payment status with the use of herbal medicines.
Partial Validation of High Performance Liquid Chromatography for Analysis of Isoniazid in Rat Plasma Novi Yantih; Siti Hafilah; Yahdiana Harahap; WAHONO SUMARYONO; Rianto Setiabudy
JURNAL ILMU KEFARMASIAN INDONESIA Vol 16 No 1 (2018): JIFI
Publisher : Fakultas Farmasi Universitas Pancasila

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1786.506 KB) | DOI: 10.35814/jifi.v16i1.497

Abstract

Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. Nicotinic acid derivatives such as isoniazid have the strongest anti-tuberculosis properties. For pharmacokinetics studying of isoniazid (INH), a method is needed to determine the levels of INH in plasma. Objective: The aim of this research is to partial validate of high performance liquid chromatography (HPLC) for analysis of INH in rat plasma. Method: For the preliminary study, rat plasma was used. The HPLC system used is a stationary phase C18 with length 250mm and temperature of 30°C, mobile phase hexane sulphonate acid 20mM pH 2.47–methanol (65:35). The analytical parameters in partial validated were linearity, lower limit of quantification (LLOQ), precision, accuracy, and recovery. Results: The results of linearity test of INH showed r value of 0.9996. LLOQ of this method was 0.1258μg/mL. The resulting accuracy and precision value met FDA requirements with a percent recovery ranging from 96.57–107.99%. Conclusion: The HPLC system was a valid method for analysis of INH in rat plasma.
Development and Validation of Simultaneous Analysis of Amlodipine Besylate and Valsartan in Spiked Human Plasma Using Liquid Chromatography Tandem Mass Spectrometry Shania Rizki Ivany; Eme Stepani Sitepu; Reynatha Pangsibidang; Yahdiana Harahap
Journal of Global Pharma Technology Volume 14 Issue 05 (2022) May 2022
Publisher : Journal of Global Pharma Technology

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Amlodipinebesylate, a dihydropyridine calcium channel blocker, and valsartan, an angiotensin II receptor blocker, are antihypertensive agents. Fixed dose combination of amlodipine and valsartan can reduce blood pressure (BP) effectively than amlodipine or valsartan monotherapy. Amlodipine and valsartan have low concentration in blood, so a highly selective and sensitive method is required. This research is aimed to obtain an optimum and validated method for determiningamlodipinebesylate and valsartan in plasma using Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS). Mass detection was performed by Waters Xevo TQD with Electrospray Ionization source at positive ion mode in the Multiple Reaction Monitoring. Amlodipine besylate, valsartan, and irbesartan were detected at m/z409.16 > 238.06; 436.22 > 291.15; and 429.22 > 207.1; respectively. The optimum analysis condition was obtained using Waters AcquityTM UPLC C18 1.7 µm (2.1 x 100 mm); the column temperature was45oC; eluted undera gradient of mobile phase of 0.1% formic acid in water and acetonitrile at a flow rate 0.2 mL/min within 6 minutes; and irbesartan as an internal standard. Sample preparation was carried out by liquid-liquid extraction with ammonium acetate and ethyl acetate; mixed with vortex for 2 minutes; centrifugated at 2043 G-force for 10 minutes; evaporated with nitrogen gas at 50oC for 10 minutes; and reconstituted with 100 µL of mobile phase. This method fulfilled the acceptance criteria of validation based on Bioanalytical Method Validation Guidance by Food and Drug Administration in 2018. This method was linear at 0.20 – 10.00 ng/mL with r ≥ 0.997357 for amlodipine and 5.00 – 6000.00 ng/mL r ≥ 0.998476 for valsartan.
The The Effect of Using Different Anticoagulant Types for Determination of Esomeprazole Levels in Human Plasma by High-Performance Liquid Chromatography Rizka Mardhiani; Yahdiana Harahap; Eme Stepani Sitepu; Sunarsih
Jurnal Multidisiplin Madani Vol. 3 No. 10 (2023): October, 2023
Publisher : PT FORMOSA CENDEKIA GLOBAL

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55927/mudima.v3i10.4170

Abstract

Esomeprazole is a Proton Pump Inhibitor (PPI) drug formulated in delayed-release tablets, that are included in the mandatory bioequivalence test. In vitro method validation used human plasma from the Indonesian Red Cross that used citrate as an anticoagulant. In the implementation of in vivo study, usually using human plasma used EDTA or heparin as an anticoagulant. This study aims to evaluate the effect of using anticoagulant types that may affect the analysis of esomeprazole in human plasma. Optimum chromatographic conditions used column C18 SunfireTM (5 μm, 250 mm x 4.6 mm); column temperature 40°C; mobile phase acetonitrile - phosphate buffer (40:60% v/v) pH 7.6; 1.0 mL/min flow rate with lansoprazole as an internal standard and wavelength 300 nm (PDA). The extraction was carried out by liquid-liquid extraction method using 500 μl plasma and 5 ml dichloromethane as extraction solvent. The result showed that the concentration range of calibration curve linearity in 5 – 1500 ng/mL. Recovery and broad peak response data of esomeprazole in plasma have significant differences between heparin-EDTA and citrate-EDTA anticoagulants (p<0.05), but there is no significant difference for the stability test. In conclusion, heparin is better than EDTA as an anticoagulant for esomeprazole bioanalysis
Co-Authors Cosphiadi Irawan Eme Stepani Sitepu Eme Stepani Sitepu HENDRI ALDRAT Maksum Radji NOVI YANTIH Reynatha Pangsibidang Rianto Setiabudy Rizka Mardhiani Shania Rizki Ivany Siti Hafilah Sunarsih Wahono Sumaryono